BioSpace News Archive

Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in February and March.

Stryker (NYSE:SYK) will participate in Citi’s 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at Citigroup Headquarters, New York, New York.

Ocuphire Pharma, Inc. today announced that clinical data from its ZETA-1 trial on a person-level scale evaluating APX3330 in diabetic retinopathy (DR) were presented at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference.

Aclarion, Inc. announced that it has completed several recent financing transactions that have significantly reduced debt and increased available cash.

Inspire Medical Systems, Inc. announced the retirement of Marilyn Carlson Nelson as Chair of its Board of Directors and the appointment of Chief Executive Officer Timothy P. Herbert to the additional role of Board Chair, to be effective at the conclusion of the Company’s Annual Meeting of Stockholders scheduled to occur on May 2, 2024.

Coherus BioSciences, Inc. announced it has entered into an agreement with Pharmakon Advisors, LP to revise the terms of its loan agreement entered in January 2022.

IntelGenx Corp. announced positive results from a proof-of-concept study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm® platform in healthy dogs and cats.

Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of TDM-105795 topical solution for Androgenetic Alopecia (AGA).

iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company’s first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation period.

Venus Medtech (02500. HK) announced today that, VenusP-Valve, the company’s in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, cleared approval from Health Canada.